EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudie

Comparative safety and efficacy of BIC/FTC/TAF versus DTG+3TC in antiretroviral treatment-naive patients with HIV as first-line regimens: A real-world cohort study

Liqin Sun, Yuxin Jiang, Stephane Isnard, Jingyi Chen, Yanjun Li, Hui Wang, Fang Zhao, Man Rao, Xinyun Jia, Jinping Huang, Jinwei Wu, Yinsong Luo und 8 weitere

BioScience Trends · 30.04.2026 · 20 (2) · 205-216

DOI: 10.5582/bst.2025.01335 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift BioScience Trends, erschienen am 30.04.2026. Verfasst von Liqin Sun und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, Guangdong, …. Hauptthemen laut MEDLINE: HIV Infections, Anti-HIV Agents, Lamivudine, Tenofovir. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir plus lamivudine (DTG+3TC) are first-line regimens for treatment-naive people with HIV (PWH), long-term real-world head-to-head comparisons of their metabolic and renal outcomes remain limited. We conducted a retrospective cohort study of ART-naive PWH initiating these regimens in China, utilizing 1:2 propensity score matching (PSM) to balance baseline covariates for 1,445 participants (901 BIC/FTC/TAF; 544 DTG+3TC). Over a 24-month follow-up, the study demonstrated comparable virologic suppression (99.7% vs. 100.0%; p = 0.623), weight changes, and cumulative incidence of metabolic abnormalities between the two groups. Conversely, although the crude 24-month incidence of eGFR decline was higher with DTG+3TC (54.8% vs. 40.7%; p = 0.039), adjusted Cox models revealed that the regimen was not independently associated with this decline (HR 1.20; 95% CI 0.97-1.48; p = 0.18).These findings indicate that both regimens offer comparable long-term virologic efficacy and metabolic safety profiles, supporting their routine clinical utility while highlighting the need for cautious interpretation of renal markers during integrase inhibitor-based therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsAnti-HIV AgentsLamivudineTenofovirAdenineHumansRetrospective StudiesPiperazinesFemaleMaleEmtricitabineHeterocyclic Compounds, 3-RingPyridonesOxazinesChinaAmidesTreatment Outcome

Stichwörter der Autor:innen

BIC/FTC/TAFDTG+3TCantiretroviral therapycohort studymetabolic complicationsweight change

Substanzen

Anti-HIV AgentsLamivudinePiperazinesTenofovirEmtricitabineAdenineHeterocyclic Compounds, 3-RingbictegravirPyridonesOxazines

Autor:innen und Institutionen

  • Department of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, Guangdong, China.
  • School of Public Health, Shenzhen University Medical School, Shenzhen, Guangdong, China.
  • Division of Hematology, Chronic Viral Illness Service, and Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
  • School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China.
  • Laboratory of Infectious Diseases, HIV/AIDS Clinical Treatment Center of Guangxi (Nanning), The Fourth People's Hospital of Nanning, Nanning, Guangxi, China.

Zitieren

APA

Sun, L., Jiang, Y., Isnard, S., Chen, J., Li, Y., Wang, H., Zhao, F., Rao, M., Jia, X., Huang, J., Wu, J., Luo, Y., Zhao, D., Liu, C., Li, X., Routy, J. P., Liu, J., He, Y., Cen, P., & Lu, H. (2026). Comparative safety and efficacy of BIC/FTC/TAF versus DTG+3TC in antiretroviral treatment-naive patients with HIV as first-line regimens: A real-world cohort study. BioScience Trends, 20(2), 205-216. https://doi.org/10.5582/bst.2025.01335

Vancouver

Sun L, Jiang Y, Isnard S, Chen J, Li Y, Wang H, et al. Comparative safety and efficacy of BIC/FTC/TAF versus DTG+3TC in antiretroviral treatment-naive patients with HIV as first-line regimens: A real-world cohort study. BioScience Trends. 2026;20(2):205-216. doi:10.5582/bst.2025.01335

BibTeX
@article{Sun2026,
  author = {Sun, Liqin and Jiang, Yuxin and Isnard, Stephane and Chen, Jingyi and Li, Yanjun and Wang, Hui and Zhao, Fang and Rao, Man and Jia, Xinyun and Huang, Jinping and Wu, Jinwei and Luo, Yinsong and Zhao, Dian and Liu, Chenye and Li, Xiaorui and Routy, Jean-Pierre and Liu, Jiaye and He, Yun and Cen, Ping and Lu, Hongzhou},
  title = {Comparative safety and efficacy of BIC/FTC/TAF versus DTG+3TC in antiretroviral treatment-naive patients with HIV as first-line regimens: A real-world cohort study},
  journal = {BioScience Trends},
  year = {2026},
  volume = {20},
  number = {2},
  pages = {205--216},
  doi = {10.5582/bst.2025.01335}
}
Kostenlos starten →